# QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

> **NCT03136406** · PHASE1,PHASE2 · TERMINATED · sponsor: **ImmunityBio, Inc.** · enrollment: 3 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine
- **DRUG:** 5-Fluorouracil
- **DRUG:** Leucovorin
- **DRUG:** nab-paclitaxel
- **BIOLOGICAL:** bevacizumab
- **BIOLOGICAL:** avelumab
- **BIOLOGICAL:** ALT-803
- **BIOLOGICAL:** aNK for Infusion
- **BIOLOGICAL:** ETBX-011
- **BIOLOGICAL:** GI-4000

## Key facts

- **NCT ID:** NCT03136406
- **Lead sponsor:** ImmunityBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-08-11
- **Primary completion:** 2017-11-22
- **Final completion:** 2019-11-01
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention
- **Last updated:** 2024-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03136406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03136406, "QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03136406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*